The Society for Immunotherapy of Cancer (SITC) hosted the “Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments” during the 37th Annual Meeting & Pre-Conference Programs on November 9, 2022. Available here are the presentation slides and video from “Session I: Cellular Targets of Combination Therapies,” as permitted by presenters.
The target audience for this workshop includes basic, translational, and clinical researchers from all work settings with an interest in combination immunotherapy approaches.
The Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments helps SITC to advance the science and application of cancer immunotherapy by providing relevant and engaging content to basic, translational, and clinical researchers. This Workshop will explore how the underlying biology of combination therapies and how those combinations may change and overcome specific mechanisms of resistance. The Workshop also aims to discuss provocative questions concerning novel combination immunotherapeutic development armed with a deeper biological understanding of how rational combinations and sequences of therapies can overcome specific resistance mechanisms, attendees will be equipped to design effective clinical trials leading to better patient outcomes.
Daniel S. Chen, MD, PhD – Engenuity Life Sciences
Philip D. Greenberg, MD, FAIO – Fred Hutchinson Cancer Research Center
Alexandra Snyder, MD – Generate Biomedicines
To view the entire program schedule (including presenter permission to post) please click here.
Program: Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments; Date: November 9, 202201:41:06